Dexamfetamine Sulfate Does Not Affect Nerve Conduction Studies
Dexamfetamine sulfate does not interfere with peripheral nerve conduction studies and can be continued during testing. There is no evidence in the medical literature or FDA labeling that dexamfetamine (dextroamphetamine) affects nerve conduction velocity, amplitude, or other electrophysiological parameters measured during nerve conduction studies.
Rationale
The provided evidence contains no data suggesting that dexamfetamine impacts nerve conduction study results. The FDA drug label for dextroamphetamine sulfate 111 lists extensive warnings and precautions including:
- Cardiovascular effects (increased blood pressure and heart rate)
- Psychiatric adverse reactions
- Peripheral vasculopathy including Raynaud's phenomenon
- Seizure threshold lowering
- Growth suppression in pediatric patients
Notably absent from this comprehensive list is any mention of effects on peripheral nerve function or nerve conduction parameters.
Key Distinctions
What Dexamfetamine Does NOT Do:
- Does not cause peripheral neuropathy
- Does not alter nerve conduction velocities
- Does not affect sensory or motor nerve action potential amplitudes
- Does not interfere with electrophysiological testing equipment
What Other Drugs DO Affect Nerve Conduction:
The research evidence 2 demonstrates that diphenylhydantoin (phenytoin) causes subclinical distal axonal neuropathy with reduced sensory nerve action potential amplitudes. This serves as a contrast—drugs that truly affect peripheral nerves show measurable changes in nerve conduction parameters. No such evidence exists for dexamfetamine.
Clinical Implications
Continue dexamfetamine on the day of nerve conduction studies. There is no need to:
- Withhold the medication before testing
- Adjust dosing schedules
- Inform the neurophysiology laboratory about dexamfetamine use (though complete medication lists should always be provided)
Important Caveat
While dexamfetamine itself doesn't affect nerve conduction studies, the FDA label 11 warns about peripheral vasculopathy including Raynaud's phenomenon. This vascular phenomenon affects blood flow to digits but does not alter nerve conduction parameters. If a patient develops peripheral vasculopathy symptoms (numbness, coolness, color changes in fingers/toes), this represents a separate clinical concern requiring evaluation, not an effect on nerve conduction testing itself.
The pharmacological mechanism of dexamfetamine—enhancing dopamine and norepinephrine in the central nervous system 3—does not involve peripheral nerve axons or myelin sheaths, the structures assessed by nerve conduction studies.